Literature DB >> 15670372

Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial.

Philippe Menei1, Laurent Capelle, Jacques Guyotat, Stéphane Fuentes, Richard Assaker, Benoit Bataille, Patrick François, Didier Dorwling-Carter, Philippe Paquis, Luc Bauchet, Fabrice Parker, Jean Sabatier, Nathalie Faisant, Jean-Pierre Benoit.   

Abstract

OBJECTIVE: This study was a randomized, multicenter Phase II trial comparing the effect of perioperative implantation of 5-fluorouracil-releasing microspheres followed by early radiotherapy (Arm A) and early radiotherapy alone (Arm B) in patients with gross total resection of high-grade glioma.
METHODS: Patients were randomized on clinical and radiological assumption of supratentorial high-grade glioma. All patients underwent surgery, and after resection and histological confirmation, patients randomized to Arm A received multiple injections of microsphere suspension (130 mg of 5-fluorouracil). Conventional fractionated radiotherapy (59.4 Gy) was initiated between the second and the seventh day after surgery for both arms.
RESULTS: A total of 95 patients were randomized. Seventy-seven patients were treated and analyzed in intention to treat for efficacy and safety. Overall survival was 15.2 months in Arm A and 13.5 months in Arm B. In the subpopulation of patients with complete resection, overall survival was 15.2 months in Arm A versus 12.3 months in Arm B. However, these differences were not significant. Safety was acceptable with prophylactic high doses of corticosteroids.
CONCLUSION: It may be hypothesized that the implantation of 5-fluorouracil-loaded microspheres in the wall of the cavity resection did increase the overall survival, but the present study was not designed and sufficiently powered to demonstrate this.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670372     DOI: 10.1227/01.neu.0000144982.82068.a2

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  22 in total

1.  A safety and toxicity assessment of the administration of multiple intracerebral injections of irinotecan or doxorubicin drug-eluting beads.

Authors:  N Held; A L Lewis; H J Hedrich; T Brinker; S Glage
Journal:  Clin Transl Oncol       Date:  2011-10       Impact factor: 3.405

2.  Response to "Glioma resection and tumor recurrence: back to Semmelweis".

Authors:  Philippe Menei; Anne Clavreul; Jean Michel Lemée
Journal:  Neuro Oncol       Date:  2016-10-07       Impact factor: 12.300

3.  Evaluation of biocompatibility and anti-glioma efficacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate.

Authors:  Silke Glage; Andrew L Lewis; Patricia Mertens; Steffen Baltes; Peter Geigle; Thomas Brinker
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

4.  Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004.

Authors:  Luc Bauchet; Hélène Mathieu-Daudé; Pascale Fabbro-Peray; Valérie Rigau; Michel Fabbro; Olivier Chinot; Loreleï Pallusseau; Charlotte Carnin; Karl Lainé; Aline Schlama; Agnes Thiebaut; Maria Cristina Patru; Fabienne Bauchet; Martine Lionnet; Michel Wager; Thierry Faillot; Luc Taillandier; Dominique Figarella-Branger; Laurent Capelle; Hugues Loiseau; Didier Frappaz; Chantal Campello; Christine Kerr; Hugues Duffau; Monique Reme-Saumon; Brigitte Trétarre; Jean-Pierre Daures; Dominique Henin; François Labrousse; Philippe Menei; Jérome Honnorat
Journal:  Neuro Oncol       Date:  2010-04-02       Impact factor: 12.300

Review 5.  Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas.

Authors:  Kaisorn L Chaichana; Leon Pinheiro; Henry Brem
Journal:  Ther Deliv       Date:  2015-03

Review 6.  Polymeric drug delivery for the treatment of glioblastoma.

Authors:  Scott D Wait; Roshan S Prabhu; Stuart H Burri; Tyler G Atkins; Anthony L Asher
Journal:  Neuro Oncol       Date:  2015-03       Impact factor: 12.300

7.  Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme.

Authors:  Klaus Maier-Hauff; Ronny Rothe; Regina Scholz; Uwe Gneveckow; Peter Wust; Burghard Thiesen; Annelie Feussner; Andreas von Deimling; Norbert Waldoefner; Roland Felix; Andreas Jordan
Journal:  J Neurooncol       Date:  2006-06-14       Impact factor: 4.130

8.  Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).

Authors:  Jessica M Grunda; L Burton Nabors; Cheryl A Palmer; David C Chhieng; Adam Steg; Tom Mikkelsen; Robert B Diasio; Kui Zhang; David Allison; William E Grizzle; Wenquan Wang; G Yancey Gillespie; Martin R Johnson
Journal:  J Neurooncol       Date:  2006-06-14       Impact factor: 4.130

9.  Nano to micro delivery systems: targeting angiogenesis in brain tumors.

Authors:  Ariel Gilert; Marcelle Machluf
Journal:  J Angiogenes Res       Date:  2010-10-08

10.  Model simulation and experimental validation of intratumoral chemotherapy using multiple polymer implants.

Authors:  Brent D Weinberg; Ravi B Patel; Hanping Wu; Elvin Blanco; Carlton C Barnett; Agata A Exner; Gerald M Saidel; Jinming Gao
Journal:  Med Biol Eng Comput       Date:  2008-06-04       Impact factor: 2.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.